Michael G. Wyllie
 | This biography of a living person needs additional citations for verification. (May 2017) (Learn how and when to remove this template message) |
| Michael G. Wyllie | |
|---|---|
| Born | 13 March 1951 (age 73) Luncarty, Perth, Scotland |
| 🏡 Residence | Shenington, Banbury, UK |
| 🏳️ Nationality | British |
| 🏫 Education |
|
| 🎓 Alma mater | University of Aberdeen |
| 💼 Occupation | |
| 👔 Employer | |
| Known for | Drug Development |
Michael Grant Wyllie (born 13 March 1951) is a British research scientist. He has developed drugs in the fields of urology and sexual health and founded several private and public companies.[3]
Early life and academic career[edit]
Wyllie was born in Luncarty, Perth, Scotland, educated at Redgorton Primary School and Perth Academy. He studied pharmacology at the University of Aberdeen in 1973 and received his PhD in Neuropharmacology from the University of Aberdeen faculty of Medicine in 1976. Initially he followed the classical academic path as a lecturer at the Department of Pharmacy, Heriot-Watt University from 1976 to 1979 but became frustrated by the unavailability of research funding.
Commercial research and business career[edit]
In 1994 Wyllie joined Pfizer HQ in New York City to the newly-created position of Director of Urology and was heavily involved in the regulatory approval and marketing of Cardura for being prostatic hyperplasia and Viagra for erectile dysfunction. Although, leaving Pfizer in 1998, he is still retained by Pfizer as a Viagra IP consultant.[4] Amongst other activities, in the early 2000s Wyllie created the specialist urology company Plethora Solutions which was listed on the London Stock Exchange and was responsible for the discovery and development of Fortacin for the treatment of premature ejaculation3456. Fortacin was launched in the UK in November 2016, will be marketed in the EU by Plethora’s marketing partner, Recordati, in late 2017 and is undergoing regulatory review in the United States. During 2016 Plethora solutions was acquired by Regent Pacific and is now listed on the Hong Kong Stock Exchange.[5] Wyllie continues in his role as Chief Scientific Officer of the Company.[1]
From 1998 onwards Wyllie has also helped establish several private and public companies, including, Axellis, Bactomed, Taihua, Plc and Vivomedica. He is chairman of the Oban-based biotechnology company, Glycomar[6] and the Welsh oncology company, Morvus.[7][2]
References[edit]
- ↑ 1.0 1.1 "Regent Pacific succeeds in pursuit of Plethora Solutions". Financial Times. Retrieved 6 May 2017. (Subscription required (help)). Cite uses deprecated parameter
|subscription=(help) - ↑ 2.0 2.1 "Morvus Technology Announces Appointment of New Chairman" (Press release). morvus.com. 1 April 2013. Retrieved 6 May 2017.
- ↑ "Michael G. Wyllie on Bloomberg". Bloomberg.com. Retrieved 6 May 2017.
- ↑ "Viagra scientist chases new sexual health breakthrough". Financial Times. Retrieved 6 May 2017. (Subscription required (help)). Cite uses deprecated parameter
|subscription=(help) - ↑ "Regent Pacific Agrees to Buy Remaining 70% of Plethora Solutions pill". thestreet.com. Retrieved 6 May 2017.
- ↑ "Glycomar's management". glycomar.com. Retrieved 6 May 2017.
- ↑ "Morvus technology on Bloomberg". Bloomberg.com. Retrieved 6 May 2017.
This article "Michael G. Wyllie" is from Wikipedia. The list of its authors can be seen in its historical. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
